BRIEF published on 07/23/2026 at 16:01, 2 months 3 days ago ABL Diagnostics falls below the 95% threshold Growth Strategy Stock Liquidity Majority Shareholder ABL Diagnostics Widening Of The Floating
BRIEF published on 07/23/2026 at 09:27, 2 months 3 days ago ABL Diagnostics takes over TEXCELL's activities Investment ABL Diagnostics Virology Genopole TEXCELL Takeover
PRESS RELEASE published on 07/23/2026 at 09:22, 2 months 3 days ago Inside Information / Other news releases ABL Diagnostics selected by the \u00c9vry Commercial Court to acquire TEXCELL's operations, enhancing life sciences and infectious diseases activities at Genopole Acquisition Molecular Diagnostics ABL Diagnostics Genopole TEXCELL
BRIEF published on 07/13/2026 at 08:05, 2 months 13 days ago Half-yearly review of the ABL Diagnostics Liquidity Contract in 2026 Liquidity Contract Stock Market Transactions ABL Diagnostics Half-year Review First Half Of 2026
BRIEF published on 06/18/2026 at 13:57, 3 months 8 days ago ABL Diagnostics: Growth and Outlook for 2026 INVEST SECURITIES Growth Partnerships Molecular Diagnosis Genotyping
BRIEF published on 06/18/2026 at 13:57, 3 months 8 days ago ABL Diagnostics Projects Notable Growth and Upward Potential Strategic Partnerships Revenue Increase Buy Recommendation ABL Diagnostics Growth 2026
PRESS RELEASE published on 06/18/2026 at 13:52, 3 months 8 days ago Inside Information / Other news releases ABL Diagnostics confirms growth trajectory with strong upside potential. Invest Securities raises target price to €8.7 and maintains 'Buy' recommendation INVEST SECURITIES Target Price Growth Trajectory Upside Potential ABL Diagnostics
BRIEF published on 06/12/2026 at 08:05, 3 months 14 days ago ABL Diagnostics and CDL Pharma sign a €2.7 million contract until 2031 Clinical Trials Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 3 months 14 days ago ABL Diagnostics and CDL Pharma Secure €2.7 Million Contract Clinical Program Neurodegenerative Diseases International Contract ABL Diagnostics CDL Pharma
PRESS RELEASE published on 06/12/2026 at 08:00, 3 months 14 days ago Inside Information / Other news releases ABL Diagnostics and CDL Pharma secure a multi-year international contract of up to €2.7 million through 2031. The contract involves services for neurodegenerative disease clinical programs across North America, Europe, and Asia Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma International Clinical Program
Published on 09/26/2026 at 01:00, 18 hours 22 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 18 hours 22 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 21 hours 7 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 1 day 1 hour ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 1 day 4 hours ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 15:30, 3 hours 52 minutes ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 4 hours 7 minutes ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 11 hours 37 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 19 hours 21 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 17:40, 1 day 1 hour ago Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:00, 2 days 1 hour ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 2 days 1 hour ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 2 days 1 hour ago Cegedim first-half 2026 results: profitability continues to improve
